Since the marker "biomass arrest" is common to both kinds of antibiotics (bactericidal and bacteriostatic) and is also the one that is routinely evaluated in the laboratory as defined by the MIC, we used this as the marker of growth arrest in our synergy simulation.
Since the biomass arrest marker is common to both kinds of antibiotics (bactericidal and bacteriostatic) and is also the one that is routinely evaluated in the laboratory as defined by MIC, we used this as the marker of growth arrest in our synergy simulation.
The diagnosis of T-LGL leukemia was established by clinical and laboratory parameters as defined previously.
The diagnosis of CKD was based on clinical and laboratory examinations as defined by the K/DOQI criteria [ 15].
Participants with abnormal physical or laboratory findings as defined below were counselled and referred to their nearest health facility for further action and follow up.
All experiments were performed under conditions described in the Guide for the Care and Use of Laboratory Animals, as defined by the National Institutes of Health.
In a cross-sectional analysis of longitudinally acquired data, demographic, clinical and laboratory correlates (as defined above) of anti-RNAP were determined, using univariate and multiple regression analyses.
Safety was assessed by adverse events (AEs), vital signs, and laboratory evaluations, as defined in e-Appendix 1. Post hoc exploratory estimation of myocardial oxygen consumption (MVO2) was carried out as defined in e-Appendix 1.
We excluded patients as cases if they were admitted directly into an intensive care unit from a hospital that was not a study site (because emergency department documentation and controls were not available), did not fulfil CDC criteria for influenza-like illness in the emergency department, or had suspected pH1N1 infection that was not confirmed by laboratory testing, as defined above.
Of the 70 patients, 13 were excluded from the present study for the presence of malignant fistula (n=1), distant metastasis (liver metastasis (n=4), lung metastasis (n=2), bone metastasis (n=3)), medical conditions (including ineligible laboratory data as defined below, n=2), or concurrent gastric cancer (n=1).
